Acute migraine: Which triptan?

Practical Neurology

Volumn 4, Issue 1, 2004, Pages 6-19

  Gladstone, Jonathan P ^a   Dodick, David W ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANTIMIGRAINE AGENT; BARBITURIC ACID DERIVATIVE; CAFFEINE; CIMETIDINE; CYTOCHROME P450 INHIBITOR; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE TARTRATE; FROVATRIPTAN; ISOMETHEPTENE; MAXALT MLT; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; NOSE SPRAY; OPIATE; PARACETAMOL; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN; ZOLMITRIPTAN ZMT;

ACUTE DISEASE; ANGINA PECTORIS; BITTER TASTE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FEEDBACK SYSTEM; HUMAN; INJECTION; ISCHEMIC HEART DISEASE; MIGRAINE; NOSE IRRITATION; RELAXATION TRAINING; REVIEW; SIDE EFFECT; SUPPOSITORY; TABLET DISINTEGRATION; TABLET FORMULATION;

EID: 1342268999     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1474-7766.2004.03-205.x     Document Type: Review

References (47)

1. Becker WL (1999) Migraine-associated symptoms: clinical significance and management. Canadian Journal of Clinical Pharmacology, 6, 15A-19A.
2. Bousser MG, D'Allens H & Richard A (1993) Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group. Journal of Internal Medicine, 234, 2116.
3. Burstein R, Cutrer MF & Yarnitsky D (2001) The development of cutaneous allodynia during a migraine attack. clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain, 123, 1703-9.
4. Charlesworth BR, Dowson AJ & Purdy A et al. (2003) Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs, 17, 653-67.
5. Dahlof CG (2001) Sumatriptan: pharmacological basis and clinical results. Current Medical Research and Opinion, 17, S35-45.
6. Dahlof CGH & Solomon G (1998) The burden of migraine to the individual sufferer: a review. European Journal of Neurology, 5, 525-33.
7. Dodick DW (in press) Triptans and chest symptoms: the role of pulmonary vasculature. Cephalalgia, in press.
8. Dodick DW, Lipton RB, Goadsby PJ et al. (2002b) Prioritizing triptan treatment attributes: a pilot study. Neurology, 58, A129.
9. Dodick DW, Lipton RB, Martin VT et al. (in press) Consensus Statement. Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine. Archives of International Medcine, in press.
10. Dodick DW, Martin V (in press) Triptans CNS side-effects. pharmacokinetic and metabolic mechanisms. Cephalalgia, in press.
11. Farkkila M, Olesen J, Dahlof C et al. (2003) Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia, 23, 463-71.
12. Ferrari MD, Roon KI, Lipton RB etal. (2001) Oral triptans (serotonin 5-HT1b/1d agonits) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 538, 1668-75.
13. Fox AW & Davis RL (1998) Migraine chronobiology. Headache, 38, 436-41.
14. Gallagher RM & Kunkel R (2003) Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache, 43, 36-43.
15. Geraud G, Keywood C & Senard JM (2003) Migraine headache recurrence: relationship to clinical, pharamacological, and pharmacokinetic properties of triptans. Headache, 43, 376-88.
16. Gladstone JP & Dodick DW (2003) Current and emerging treatment options for migraine and other primary headache disorders. Expert Review of Neurotherapeutics, 3, 845-72.
17. Gladstone JP & Gawel M (2003) Newer formulations of the triptans. Advances in patient management. Drugs, 63, 2285-305.
18. Goadsby PT, Lipton RB & Ferrari MD (2002) Migraine -current understanding and treatment. New England Journal of Medicine, 346, 257-70.
19. Hamelsky SW, Stewart WF & Lipton RB (2001) Epidemiology of migraine. Current Pain and Headache Reports, 5, 189-94.
20. Hu XH, Markson LE & Lipton RB et al. (1999) Burden of migraine in the United States: disability and economic costs. Archives of Internal Medicine, 159, 813-8.
21. Humphrey PPA (2001) How it started. Cephalalgia, 21, 2-5.
22. International Headache Society Committee on Clinical Trials in Migraine. (1991) Guidelines for controlled trials of drugs in migraine, ed 1. Cephalalgia, 11, 1-12.
23. Krymchantowski AV & Barbosa JS (2002) Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia, 22, 309-12.
24. Lipton RB & Stewart WF (1999) Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache, 39, S20-S26.
25. Lipton RB, Stewart WF, Diamond S et al. (2001) Prevalence and burden of migraine in the United States: data from the American Migraine II Study. Headache, 41, 646-57.
26. MacGregor EA, Brandes J & Eikermann A (2003) Migraine prevalence and treatment patterns. the global migraine and zolmitriptan evaluation survey. Headache, 43, 19-26.
27. Mannix LK (2003) Management of menstrual migraine. The Neurologist, 9, 207-13.
28. Mathew NT, Hettiarachchi J & Alderman J (2003) Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache, 43, 962-74.
29. Mathew NT, Kailasam J, Gentry P et al. (2000) Treatment of non-responders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache, 40, 464-5.
30. Menken M (1996) The ambulatory workload of office-based neurologists: implications of the national ambulatory medical survey. Archives of Neurology, 53, 379-81.
31. Menken M, Munsat TL & Toole JF (2000) The global burden of disease study: implications for neurology. Archives of Neurology, 57, 418-20.
32. Nappi G, Sandrini G & Sances G (2003) Tolerability of the triptans: clinical implications. Drug Safety, 26, 93-107.
33. Oldman AD, Smith LA & McQuay HJ et al. (2002) Pharmacological treatments for acute migraine: quantitative systematic review. Pain, 97, 247-57.
34. Pascual J (2002) Clinical benefits of early triptan therapy for migraine. Headache, 42, 10-7.
35. Rajput AH, Uitti RJ & Rajput AH (1988) Neurological disorders and services in Saskatchewan - a report based on provincial health care records. Neuroepidemiology, 7, 145-51.
36. Rapoport AM (2003) Tepper SJ. Bigal ME. Sheftell FD. The triptan formulations: how to match patients and products. CNS Drugs, 17, 431-47.
37. Salonen R (2002) Drug comparisons: why are they so difficult? Cephalalgia, 20, 25-32.
38. Saper JR (2001) What matters is not the differences between triptans, but the differences between patients. Archives of Neurology, 58, 1481-2.
39. Sempere AP, Mola S, Medrano V et al. (2002) Descriptive epidemiology of ambulatory neurological care in the Vega Baja (Alicante) area. Review of Neurology, 35, 822-6.
40. Sheftell FD & Tepper SJ (2002) New paradigms in the recognition and acute treatment of migraine. Headache, 42, 58-69.
41. Silberstein SD (1995) Migraine symptoms: results of a survey of self-reported migraineurs. Headache, 35, 387-96.
42. Silberstein SD & US Headache Consortium (2000) Practice Paramenter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology, 55, 754-62.
43. Stark S, Spierings EL, McNeal S et al. (2000) Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache, 40, 513-20.
44. Tepper SJ & Millson D (2003) Safety profile of the triptans. Expert Opinions in Drug Safety, 2, 123-32.
45. Tfelt-Hansen P, Block G, Dahlof C et al. (2000) Guidelines for Controlled Trials of Drugs in Migraine, 2nd edn. Cephalalgia, 20, 765-86.
46. Volans GN (1978) Migraine and drug absorption. Clinical Pharmacokinet, 3, 313-8.
47. Winner P, Adelman J, Aurora S et al. (2003) Pain-free results of sumatriptan 6mg SC in the treatment of morning migraine. Cephalalgia, 23, 703-4.